COMMUNIQUÉS West-GlobeNewswire

Family Insight Appoints Kyle Williamson as Vice President of Business Development, Accelerates Expansion and Partnerships in Value-Based Care
19/02/2026
RICHMOND, Va., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Family Insight, PC , a Whitecap Care, LLC company and a leader in value-based care (VBC) and behavioral health, announces the appointment of Kyle Williamson as vice [...]
Burcon Chiropractic Launches Meniere’s Disease Treatment Clinical Trial in Grand Rapids
19/02/2026
Trial #MDTCT2026 Now Enrolling 50 Participants Diagnosed with Unilateral Meniere’s Disease Grand Rapids, Michigan, U.S.A., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Burcon Chiropractic Announces Clinical Trial for Meniere’s [...]
Klothea Bio Announces the Launch of a Phase 1b Clinical Trial of AKL003, an Alpha Klotho mRNA Therapeutic, for the Extension of Human Lifespan
19/02/2026
MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Klothea Bio, Inc. (“Klothea Bio”), a clinical-stage biotechnology company developing therapeutics based on their proprietary serum klotho platform, today announced the launch of [...]
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
19/02/2026
Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic [...]
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
19/02/2026
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care [...]
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
19/02/2026
Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations Espoo, Finland, 19 February 2026: Herantis Pharma Plc (“Herantis”), a [...]
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
19/02/2026
Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partner Mediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab [...]
Aaptiv Launches New MSK App in Partnership With movr
19/02/2026
Movement Health Solution Provides Clinical-Grade Care for Musculoskeletal Pain and Recovery CARLSBAD, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Aaptiv, a leading fitness and wellness platform for employers, today [...]
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
19/02/2026
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the world As a [...]
Step Pharma secures €2.5 million EIC grant to accelerate development of dencatistat for CTPS2 null gynaecological tumours
19/02/2026
Blended finance award also includes up to €10 million in equity investment from the EIC Step Pharma’s lead product, dencatistat, expected to begin evaluation in phase 1b expansion cohorts for CTPS2 null ovarian and [...]
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
19/02/2026
CDI ‑ 988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections Company to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory [...]
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
19/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat [...]
INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”
19/02/2026
Strategic Transaction Advances Company’s Growth SARASOTA, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment [...]
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
19/02/2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will [...]
Microbot Medical®’s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference
19/02/2026
Global Robotic Leaders Convene to Discuss & Highlight Surgical Advancements of the Next Decade with a Special Focus on the Endovascular Space HINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. ( [...]
Catheter Precision Announces Strategic Sale of Non-Core Assets to Strengthen Balance Sheet and Accelerate Electrophysiology Growth
19/02/2026
Upfront Cash, Equity Participation and Tiered Royalty Structure Providing Long-Term Revenue Upside FORT MILL, S.C., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a leader in advanced [...]
Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation
19/02/2026
THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
19/02/2026
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of [...]
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
19/02/2026
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would [...]

Pages